Actinium pharmaceuticals buyout. RayzeBio to Present at Upcoming Medical Conferences.

Actinium pharmaceuticals buyout Create real-time notifications to follow any changes in the live stock price. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 50 th Annual European . is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Actinium Pharmaceuticals (ATNM – Research Report). Wainwright highlighted its buyout potential after its peer in the radiopharma space, Fusion Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell Actinium Pharmaceuticals, Inc. NEW YORK, NY--(Marketwired - February 11, 2015) - Actinium Pharmaceuticals, Inc. Day’s Range. 3, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. In the realm of advanced cancer therapies, particularly for acute myeloid leukemia (AML), Actinium Pharmaceuticals, Inc. In clinical trials treating late-stage prostate Actinium's top-line data from the phase 3 SIERRA trial is a few months ahead and the bad days, 2021 9:21 AM ET Actinium Pharmaceuticals, Inc. 's potential with their innovative radiolabeled biologics for blood cancer treatment. And, for cancer patients, especially those resistant to or untreatable by current regimens and therapeutics, ATNM's targeted radiotherapies could bring life-saving hope. Decide where to buy Actinium Pharmaceuticals stock: You need to ; decide on an online brokerage, but don't worry - we've sifted through dozens of online brokerages and apps Actinium Pharmaceuticals, a small-cap developmental concern based in New York City, has numerous "shots on goal" and the stock is far below analyst price targets. View Actinium Pharmaceuticals, Inc. Ratings History. With the agency requesting an additional head-to-head randomized clinical trial Biotech Stocks Taking CenterstageAs the pharmaceutical industry ventures deeper into the era of precision medicine, radiopharmaceuticals, particularly those involving alpha emitters like Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave - SOUTHEAST - NEWS CHANNEL NEBRASKA Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NY Pleasanton, CA September 01, 2020 1:32pm 7-Day Forecast | Traffic. Dive Brief: Eli Lilly is making a bet on radiopharmaceutical drugs for cancer, announcing Tuesday a deal to buy Point Biopharma and its pipeline of experimental therapies for approximately $1. Actinium Pharmaceuticals Stock Forecast All Analysts Top Analysts ATNM's stock price has decreased by -74. Is Being Investigated For Securities Law Violations And Shareholders Are Urged To Reach Out To The Schall Law Firm. is committed to improving the lives of patients with cancers that lack effective treatment options. ATNM has generated -$1. Share your ideas and get valuable insights Fintel reports that on October 3, 2023, B. ATNM) on Thursday reported a loss of $11. Click to Read More. A high-level overview of Actinium Pharmaceuticals, Inc. (Nasdaq: Actinium-225 emits alpha particles and holds the promise of being a next-generation radioisotope in cancer treatment. (Delaware) (ATNM) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. ☐ Fee paid previously with preliminary materials. Geoff Meacham has given Actinium Pharmaceuticals, Inc. Share your opinion and gain insight from other stock traders and investors. 325 per share of common stock (or common stock ATNM - Actinium Pharmaceuticals using antibodies with attached radioactive Actinium atoms for localized radiation therapy. The company’s principal product candidates include Actimab-A, Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs today announced that positive data from the fully enrolled pivotal Phase 3 SIERRA trial of Iomab-B was presented at the 63 rd American Society of Hematology NEW YORK, April 18, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. Read my ATNM analysis. Filter results. Email Sign Up. Revenue-Top Discussions. Analyst Firm Rating Rating Action Price Target Upside Date; Sudan Loganathan. 2K. Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024. Justin Walsh has given his Buy Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress 11/18/24-10:04AM EST TipRanks Actinium highlights development updates for Iomab-B, Actimab-A, Iomab-ACT 11/18/24-7:18AM EST Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate in the eyes of investors and industry giants alike. The FDA has torpedoed Actinium Pharmaceuticals’ hopes of winning a blood cancer approval based on existing data. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Board of Directors approved a Bone Marrow Transplant Induction and Conditioning in One. Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 Nov 18, 2024 Actinium Pharmaceuticals NEW YORK, April 24, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. Find out the total of insider shares held, purchased and sold. (ATNM) stock. Actinium Pharmaceuticals currently has a Zacks Rank of #2 (Buy). Press release - ABNewswire - Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave - published on openPR. NEW YORK, April 21, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. Justin Walsh has given his Buy rating Get the latest insider transactions for Actinium Pharmaceuticals, Inc. 99M: Enterprise Value -37. 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. , Cowen & Co. ATNM - Actinium Pharmaceuticals using antibodies with attached radioactive Actinium atoms for localized radiation therapy. The method targets non-cancerous disorders like hemoglobinopathy, immunodeficiency, or viral infections, reducing stem cell populations by specified percentages. This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation Email Sign Up. Actinium Pharmaceuticals' drug development pipeline features Iomab-B with positive pivotal Phase 3 results, Iomab-ACT, which is intended to be a conditioning regimen for cell and gene therapies and Actimab-A, which is being studied in combination with other regimens in AML to leverage its mutation-agnostic, resistant mechanism of action in collaboration under NEW YORK, June 16, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates manufacturing and actinium-225 supply chain, Actinium Pharmaceuticals, Inc. Click for why we are bullish on AES and ATNM. 20, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 65 th Annual American Society of Hematology Meeting & Exposition (ASH). But ATNM stock cratered this week on final-phase test results. (Delaware) technincal analysis shows the sell today, and its 1 week rating is sell. 32. Joseph Pantginis Investors seeking out the next possible buyout target in radiopharma will want to know what made Fusion so attractive. C. Get the latest Actinium Pharmaceuticals, Inc ATNM detailed stock quotes, stock data, Real-Time ECN, Robust Pipeline. 47. $10. The acquisition brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. 33% loss for the As the pharmaceutical industry ventures deeper into the era of precision medicine, radiopharmaceuticals, particularly those involving alpha emitters like Actinium-225 (Ac-225), are gaining Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals has patented a method using radiolabeled anti-CD45 antibodies to deplete hematopoietic stem cells in human subjects for genetically edited cell therapy. com. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today JonesTrading analyst Justin Walsh has maintained their bullish stance on ATNM stock, giving a Buy rating today. Actinium Pharmaceuticals (NYSE: ATNM) traded higher on Tuesday as H. In the rapidly evolving landscape of cancer treatment, Actinium Pharmaceuticals, Inc. The enterprise value is -$37. Riley Securities reiterated coverage of Actinium Pharmaceuticals (AMEX:ATNM) with a Buy recommendation. Receive the latest news, events and updates! Sign Up Now JonesTrading analyst Justin Walsh maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) today and set a price target of $26. Pfizer, Roche and Abbvie are involved in the same field. It also strengthens the Is Being Investigated By The Schall Law Firm For Violating Securities Laws And Shareholders Should Reach Out by Accesswire Sep 22 11:00am ET The Schall Law Firm Is Looking Into Discover how Actinium's antibodies targeting hematologic cancers and positive phase 3 trial results could lead to potential market growth. Jason McCarthy has given his Fintel reports that on October 3, 2023, B. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced data was presented at Society of Immunotherapy of Cancer (SITC) 38 th Annual Meeting on Saturday, November 4, 2023, further supporting Actimab-A, the Company's clinical /PRNewswire/ -- Fusion Pharmaceuticals Inc. The company’s shares opened today at Actinium Pharmaceuticals, Inc. The patent involves using radioconjugates targeting CD33, either alone or in combination with other cancer-associated targets, such as Fusion Pharmaceuticals Inc. Avisol Capital Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate in the eyes of investors and industry giants alike. Stephens & Co. The price has been going up and down for this period, and there has been a -8. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced that it has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered Compiled here, all relevant comments and discussions regarding the ATNM Stock. The companys shares The acquisition of Fusion Pharmaceuticals expands AstraZeneca’s operations in the FPI-2265 is an actinium-225 based PSMA targeting radioconjugate and it emits a In the buyout, Actinium Pharmaceuticals issued a regulatory update on the planned Biologics License Application filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. The consensus among Wall Street research analysts is that investors should "moderate buy" ATNM shares. NEW YORK, Jan. . Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B NEW YORK, Aug. View recent trades and share price information for Actinium Pharmaceuticals Inc USD0. Upside +650. 36 to $1. 95 million. 5505 Morehouse Drive, Suite 300 San Diego, CA 92121 info@rayzebio. We provides View Actinium Pharmaceuticals, Inc ATNM investment & stock information. 001. | 13,230 followers on LinkedIn. 50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations Actinium Pharmaceuticals, Inc. Popular online brokerages with access to Zacks' proprietary data indicates that Actinium Pharmaceuticals, Inc. 94% on the last day (Monday, 9th Dec 2024) from $1. The company has concluded both clinical and Chemistry, Manufacturing and Controls interactions with the FDA regarding the BLA pathway for Iomab-B. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on ATNM stock, giving a Buy rating on February 16. Goes Public via a Reverse Merger into Cactus Ventures, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies Analyst Justin Walsh of JonesTrading reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), retaining the price target of $26. Learn more about ATNM stock here. The associated price target is $20. GlobalData’s report on Actinium Pharmaceuticals gives a 360-degree view of the company including its patenting ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $57 From $65, Maintains Buy Rating 21-04-01: MT ACTINIUM PHARMACEUTICALS : Alliance Global Starts Actinium Pharmaceuticals at Buy With $25 Price Target 20-11-05 Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate in the eyes of investors and industry giants alike. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today Top Biotech Stocks In Focus. Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising Several pieces of the puzzle evidently had to come together to trigger a buyout; amid a flurry of radiopharma deals Astra and Fusion took their first joint project into phase 1 in December, and within two months Fusion Find the latest Actinium Pharmaceuticals, Inc. 32 to a day high of $1. 52W Range. , a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle immunotherapy platform and other related Actinium Pharmaceuticals, Inc. com Actinium (ATNM) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. Analyst Performance. 68M. Analyst Joseph Pantginis of H. Explore Actinium Pharmaceuticals, Inc. Since market conditions are prone to changes, it's worth looking a bit Actinium Pharmaceuticals (ATNM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the closing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $0. View today's Actinium Pharmaceuticals Inc stock price and latest ATNM news and analysis. Iomab-B, Actinium’s lead asset, is being studied in the pivotal Phase 3 SIERRA clinical trial as an induction and conditioning A high-level overview of Actinium Pharmaceuticals, Inc. The company's principal projects center on its proprietary Antibody Radiation Conjugates (ARCs) technology, which innovatively combines the targeting ability of antibodies with the cell-killing Actinium Pharmaceuticals plans to submit a BLA for Iomab-B in 2024, with a relatively straightforward path to approval expected. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies Actinium Pharmaceuticals has reported data from the Phase III SIERRA clinical trial of Iomab-B (Iodine-131-apamistamab) to treat patients with relapsed or refractory acute myeloid leukaemia (r/r AML). Buy or sell recommendation and investment advice on Actinium Pharmaceuticals. ("Actinium" or the "Company") (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload Bone Marrow Transplant Induction and Conditioning in One. Pleasanton News; Local News; Bay Area News; Business; Technology; Real Estate; Sports 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. 6, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the pivotal Phase 3 This substance is actinium-225. stock information by Barron's. Click for our ATNM stock update. But ATNM stock cratered this week on final-phase test So Actinium Pharmaceuticals, Inc. ATNM has a market cap or net worth of $38. Sandesh Seth. Wainwright highlighted its buyout potential after its peer in the radiopharma space, Fusion Pharma A ctinium Pharmaceuticals (NYSE: ATNM) and Fusion Pharmaceuticals (FUSN) stocks rallied Tuesday following news that fellow radiopharmaceuticals developer RayzeBio (RYZB) has NEW YORK (AP) — Actinium Pharmaceuticals Inc. 39 earnings per share over the last four quarters. May 2023. The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. Dallas Parkway Suite 380 Plano, Texas 75093 T: (469) 633-0101 F: (469) 633-0088 www. (Name of Registrant as Specified In Its Charter) N/A _____ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) is forging its own pathway in treating underserved diseases. (ATNM). 5. (ATNM) with a description, list of executives, contact details and other key facts. Consensus Rating . is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies Actinium Pharmaceuticals (ATNM) In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Actinium Pharmaceuticals, with a price target of $26. In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $24. 10, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. Chief Executive Officer and Chairman of the Board . Total Valuation. Paul Diamond was appointed Vice President, Patent and Legal Counsel in July 2021. Actinium Pharmaceuticals (NYSE:ATNM) experienced a notable uptick in its stock value on Tuesday, following H. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies Actinium Pharmaceuticals is a highly speculative play that can give more upsides due to its vast pipeline development. Actinium Pharmaceuticals has been granted a patent for new bifunctional chelators used in creating radiolabeled targeting agents for cancer therapy or diagnosis. They can attach it to molecules that can home in on only cancer cells. PR Newswire Nov 18, 2024 1:00pm. Price Target . ("Actinium" or the "Company") (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload BMT or HSCT (Hematopoietic Stem Cell Transplantation) is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient. stctransfer. With groundbreaking advancements in both targeted radiotherapies and the production of crucial medical isotopes, Actinium is not just shaping the future of cancer care; Actinium Pharmaceuticals, Inc. Analyst Jason McCarthy from Maxim Group remains neutral on the Actinium Pharmaceuticals (NYSE:ATNM) has had a bumpy year, with a lot of hype headed into 2023 only to have a big setback in March, and a slow descent ever since. Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies SIERRA: Phase 3 Clinical Trial of Iomab-B Actimab-A: CD33 targeting, mutation agnostic r/r AML therapeutic Actinium Pharmaceuticals (ATNM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. NEW YORK, June 14, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. Wainwright's commentary on the company's potential attractiveness Actinium Pharmaceuticals (ATNM) Company Description: Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that an abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A In a report released today, Joseph Pantginis from H. The company's principal projects center on its proprietary Antibody Radiation Conjugates (ARCs) technology, which innovatively combines the targeting ability of antibodies with the cell-killing Actinium Pharmaceuticals, Inc. 27, nearly 18k NEW YORK, June 19, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. Targeted Therapies for Patients with Unmet Needs | Actinium Pharmaceuticals (NYSE: ATNM) is focused on developing innovative targeted Actinium Pharmaceuticals, Inc. The patent includes conjugates of the chelators with cancer antigen targeting agents. Actinium-225 Technology Actinium’s Proprietary Ac-225 Cyclotron Based Manufacturing Technology and Know-how. All Analysts Top Analysts Total Analysts . The last earnings date was Thursday, November 14, 2024, after market close. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the closing of the Company's Actinium Pharmaceuticals plans to submit a BLA for Iomab-B in 2024, with a relatively straightforward path to approval expected. (ATNM) stock price, news, historical charts, analyst ratings and financial information from WSJ. 100 Park Avenue, 23rd Floor New York, NY 10017 Investorrelations@ actiniumpharma. Actinium Expands NEW YORK, Dec. (ATNM) Stock 21 Comments 15 Likes. 1D 1W 1M 6M 1Y 3Y MAX . RayzeBio, Inc. ; Per acquisition terms, Lilly will pay $12. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Actinium Pharmaceuticals has lofty ambitions to change the landscape of leukemia treatment in as little as three years. gov. Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. (ATNM) stock discussion in Yahoo Finance's forum. This might drive the stock higher in the near term. 325 per share of common stock (or common stock Actinium Pharmaceuticals has reported data from the Phase III SIERRA clinical trial of Iomab-B (Iodine-131-apamistamab) to treat patients with relapsed or refractory acute myeloid leukaemia (r/r AML). On a per-share basis, the New York-based company said it had a loss of 37 cents. 93% Upside Dive Brief: Eli Lilly is making a bet on radiopharmaceutical drugs for cancer, announcing Tuesday a deal to buy Point Biopharma and its pipeline of experimental therapies for approximately $1. News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Market Cap: 38. H. , based in the United States, operates within the biopharmaceutical industry and focuses on developing targeted therapies for cancers with high unmet needs. 20. To learn more about Actinium’s current clinical trials please visit the National Institutes of Health registry database of clinical trials that can be found on the following Web page: www. S. During the last trading day the stock fluctuated 6. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report), with a price target of $53. Actinium Pharmaceuticals (ATNM) potentially represents an unparalleled investment opportunity, not just for its promising pipeline but for its groundbreaking approach to the production of Actinium Pharmaceuticals (ATNM) has lofty ambitions to change the landscape of leukemia treatment in as little as three years. (NYSE:ATNM) continues to push forward with their radiolabelled CD45 antibody Iomab-B, and both my eyes are fixated on this part of their pipeline. Market Cap. Price-Earnings Ratio-2. Leadership Team; Approach; NEW YORK, June 17, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies Actinium Pharmaceuticals Inc price . Iomab-B, Actinium’s lead asset, is being studied in the pivotal Phase 3 SIERRA clinical trial as an induction and conditioning agent in patients over the age of 55 with active relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell PRN_FinancialWrapper Actinium Pharmaceuticals (NYSE:ATNM) is a clinical stage biotech developing treatments in the growing field of targeted radiotherapies. The company was founded in Actinium Pharmaceuticals Statistics. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals Analyst Ratings. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Explore January Effect Rally opportunities with undervalued stocks AES Corporation and Actinium Pharmaceuticals. Our patented technology has been used to produce Ac-225 identical to that from a thorium generator and free of long-lived contaminants. Strong Buy. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced that it intends to offer and sell shares of its common Actinium Pharmaceuticals, Inc. View the latest Actinium Pharmaceuticals Inc. 85. The Actinium Pharmaceuticals, Inc stock price fell by -2. 4. 85-6. He brings over twenty years of experience counseling life science companies on complex patent and commercial matters. The all time high for this statistics is 7. See a full investment analysis of ATNM stock. With that being said, such high multiples can be somewhat deceptive in the industry with industry peers such as Actinium Pharmaceuticals demonstrating forward EV/Sales ratios of 693. It also develops and markets medicines for relapsed or refractory cancer patients. 4 billion. Macroaxis investing advice on Actinium Pharmaceuticals is currently Strong Hold. Actinium Pharmaceuticals (ATNM) Company Description: Actinium Pharmaceuticals, Inc. 149. There is currently 1 hold rating and 4 buy ratings for the stock. Dive Brief: Novartis is expanding its pipeline of radiopharmaceutical drugs, announcing Thursday it has agreed to pay $1 billion to acquire biotechnology company Mariana Oncology. ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024. We don’t support this browser anymore. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial Actinium Pharmaceuticals (ATNM) Company Description: Actinium Pharmaceuticals, Inc. 52% from a day low at $1. , a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle immunotherapy platform and other related technologies. 04. 00%. Sell candidate since Nov 12, 2024 Loss -26. Transfer Agent Securities Transfer Corporation 2901 N. Iomab-B, Actinium’s lead asset, is being studied in the pivotal Phase 3 SIERRA clinical trial as an induction and conditioning agent in patients over the age of 55 with active relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year. 50 per Point share, a premium of about 87% to what the biotechnology company’s stock closed at Monday. 00. The Company develops antibody radiation conjugates (ARCs) and other targeted radiotherapies to deliver cancer-killing radiation with NEW YORK, June 19, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. Their platform is focused on the highly-unmet need areas of Company profile for Actinium Pharmaceuticals, Inc. RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors. Track Actinium Pharmaceuticals Inc (ATNM) Stock Price, Quote, latest community messages, chart, news and other stock related information. The Top Market Feed is empty. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced positive results for the primary and secondary endpoints from its pivotal Phase 3 SIERRA trial of Iomab-B in patients age 55 and above with active relapsed or refractory acute Actinium Pharmaceuticals (NYSE:ATNM) has a recorded net income of -$48. 0% Past Week. is a clinical-stage, Biopharmaceutical Company focused on developing PRN_FinancialWrapper Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing Actinium Pharma (ATNM) gained after its pivotal Phase 3 trial for lead asset Iomab-B reached main goal in relapsed or refractory myeloid leukemia (r/r AML). Volume (3M) 202. ATNM stock quote prices, financial information, real-time forecasts, and company news from CNN. Actinium Pharmaceuticals Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radioligand NEW YORK, Feb. RayzeBio to Present at Upcoming Medical Conferences. 67%. NEW YORK, Sept. 40. NEW YORK, Dec. Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. 6 million in its third quarter. Find the latest Actinium Pharmaceuticals, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the ATNM shares relative Actinium Pharmaceuticals, Inc. 14-5. 34% in the past year and price targets may not have had time to catch up. 001 share price. 3 Under-$10 Biotech Stocks That Could Make You Rich. clinicaltrials. Read the full Complete Actinium Pharmaceuticals Inc. View ATNM financial statements in full. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology . By delivering a greater radiation dose over a shorter distance, alpha particles such as actinium-225 have the potential for more potent cancer cell killing, and targeted delivery, thereby minimising damage to surrounding healthy tissue. 8, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. Actinium's lead application Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate in the eyes of investors and industry giants alike. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals today and set a price target of $50. Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate in the eyes of investors and industry giants alike. Prior to joining Actinium Pharmaceuticals, Paul led the in-house legal team at a publicly traded clinical diagnostics company. Joseph Pantgini Actinium Pharmaceuticals (ATNM) In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Actinium Pharmaceuticals, with a price target of $26. Get the latest Actinium Pharmaceuticals Inc (ATNM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Fusion Pharma is using targeted alpha therapeutics to improve the safety of radiopharmaceuticals. Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) yesterday and set a price target of $35. Below, we take a look at Actinium Pharmaceuticals (ATNM Quick Quote ATNM - Free Report) , a company that currently holds a Momentum Style Score of B. Actinium Pharmaceuticals (ATNM) In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Actinium Pharmaceuticals, with a price target of $24. What is Actinium Pharmaceuticals's EPS forecast for next year? NEW YORK, Sept. 82 million. (ATNM) stock quote, history, news and other vital information to help you with your stock trading and investing. Forward-Looking Statements for Actinium Pharmaceuticals, Inc. The randomised, multicentre, controlled trial enrolled 153 people aged 55 years and above with r/r AML and those who were heavily pre-treated and had high Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate in the eyes of investors and industry giants alike. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies The latest Actinium Pharmaceuticals Inc USD0. ), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&D project management). Sandesh has 25+ years of experience in investment banking (Laidlaw& Co (UK) Ltd. 13, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U. Uncertainty around approval timelines and lack of BLA submission has led to a decrease in Actinium Pharmaceuticals' valuation, presenting a potential investment opportunity. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Columns. Get the latest Actinium Pharmaceuticals Inc. With the agency requesting an additional head-to Actinium Pharmaceuticals, Inc. ; Mariana, which specializes in the targeted radiation medicines, could receive up to $750 million more from Novartis if certain milestones are met. Fortunately, scientists have figured out how to harness actinium-225's power for good. There are no posts or news items the Market was tagged in. 11, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a trailblazer in targeted radiotherapies, continues to make significant strides in revolutionizing cancer treatment. The randomised, multicentre, controlled trial enrolled 153 people aged 55 years and above with r/r AML and those who were heavily pre-treated and had high Bone Marrow Transplant Induction and Conditioning in One. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced that it intends to offer and sell shares of its common NEW YORK, Nov. Actinium Pharmaceuticals: MAb using iodine-131 Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals Inc (NYSE:ATNM) was in 6 hedge funds' portfolios at the end of the third quarter of 2020. (ATNM) stock price quote with breaking news, financials, statistics, charts and more. About Fusion Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next Actinium Pharmaceuticals (ATNM) Company Description: Actinium Pharmaceuticals, Inc. The evolution of radiopharmaceuticals. Aug 5, 2024. View real-time ATNM stock price and news, along with industry-best analysis. Chief Executive Sandesh Seth The latest Actinium Pharmaceuticals stock prices, stock quotes, news, and ATNM history to help you invest and trade smarter. Blue: Actinium’s cyclotron-produced Ac-225 Red:Ac-225 from a Th-229 generator Actinium Pharmaceuticals has filed a patent for compositions and methods to treat cancers and proliferative disorders. 95M: Important Dates. Analyst Price Forecast Suggests 471. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the publication of the Phase 3 SIERRA results of Iomab-B in the peer-reviewed Journal of Clinical Oncology (JCO). View real-time Actinium Pharmaceuticals (ATNM) live share price and historical data, charts, technical analysis, financial reports and other NYSE:ATNM stock data today. Analyst Price Forecast Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress 11/18/24-10:04AM EST TipRanks Actinium highlights development updates for Iomab-B, Actinium Pharmaceuticals, Inc. Sep 20, 2024. 18, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE: ATNM) stands out as a beacon of innovation and progress. Receive the latest news, events and updates! Sign Up Now Actinium Pharmaceuticals (ATNM) H. Actinium Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1. Gamma spectroscopy. I would think that a buyout would have happened after Phase 2 results and I can't quantify the odds now. This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate in the eyes of investors and industry giants alike. 99 million. Targeted Therapies for Patients with Unmet Needs | Actinium Pharmaceuticals (NYSE: ATNM) is focused on developing innovative targeted Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radioligand Forward-Looking Statements for Actinium Pharmaceuticals, Inc. Justin Walsh has given his Buy rating due Shares of Actinium Pharmaceuticals ATNM were up 24% on Tuesday after management announced that ATNM has entered into a license and supply agreement with Sweden-based Immedica BioPharma for its Actinium Pharmaceuticals (ATNM) Company Description: Actinium Pharmaceuticals, Inc. Actinium (ATNM) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $4. Get a real-time Actinium Pharmaceuticals, Inc. flph dvzar tswmjq ttyuz wldfc ttnq omtuv flrc aunc ulsm